{"brief_title": "A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With COPEGUS (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C Infection (CHC).", "brief_summary": "The effects of treatment with different doses of PEGASYS in combination with different doses of ribavirin will be evaluated in patients with CHC genotype 1 who have a high viral titer, body weight greater than 85kg (187lbs) and no prior treatment with interferon. The anticipated time on study treatment is 3-12 months and the target sample size is 100-500 individuals.", "condition": "Hepatitis C, Chronic", "intervention_type": "Drug", "intervention_name": "peginterferon alfa-2a (PEG-IFN alfa-2a) [Pegasys]", "description": "270 micrograms sc weekly for 48 weeks", "arm_group_label": "PEG-IFN Alfa-2a 270 \u03bcg + Ribavirin 1600 mg", "criteria": "Inclusion Criteria: - adult patients >=18 years of age; - body weight >85kg (187lbs); - CHC (genotype 1); - liver biopsy (in <24 calendar months of first dose), with results consistent with CHC infection; - use of 2 forms of contraception during study and 6 months after the study in both men and women. Exclusion Criteria: - women who are pregnant or breastfeeding; - male partners of women who are pregnant; - conditions associated with decompensated liver disease; - other forms of liver disease, including liver cancer; - human immunodeficiency virus infection; - previous treatment with an interferon, ribavirin, viramidine, levovirin or amantadine.", "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "id": "NCT00077649.xml"}